Houston, TX – 25 January, 2017 – Medical device firm Procyrion, Inc. announced today that they are working with Millar, Inc. to test Millar’s Transcutaneous Energy Transfer (TET) Technology with Procyrion’s Aortix device, the world’s first catheter-deployed circulatory assist device intended for ambulatory use in chronic heart failure patients. Millar and Procyrion received a grant to incorporate the TET technology into the Aortix system.
Millar’s TET technology was developed to provide implantable medical devices with continuous power delivery while eliminating the need to pass a power lead through the skin. TET uses magnetic fields to transfer energy from a coil mounted outside the body across the intact skin to a coil implanted inside the body. Eliminating the indwelling power lead can reduce or eliminate driveline infections, one of the complications that has plagued implantable blood pumps for decades.
Procyrion has previously worked with Millar using their suite of pre-clinical and clinical pressure-volume loop solutions for cardiac function analysis to characterize the hemodynamic effects of the Aortix device in vivo. Now Procyrion and Millar are working together to test the patented TET technology in animals.
“Our goal is to provide the best possible solution for the millions of people who suffer from heart failure”, said Ben Hertzog, CEO of Procyrion. “We are always looking for ways to enhance Aortix using innovative technologies and the collaboration with Millar does just that.”
The Aortix device, built around a powerful micro-motor mounted on a set of expandable struts, is designed to rest the heart by reducing afterload and improving blood flow to vital organs. Unlike other circulatory assist devices – including ventricular assist devices (VADs) – that involve invasive, high risk surgical procedures, Aortix is small enough (6mm wide and less than 6.5cm long) to allow deployment without surgery and with minimal procedural risk.
“Procyrion is an excellent example of the ‘Millar customer’ who combines cutting edge technology with advanced medical insight to create novel solutions for the world’s healthcare problems,” said Tim Daugherty, CEO of Millar. “This grant gives us the opportunity to further test our technology with their ground-breaking heart pump.”
ABOUT PROCYRION
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.
For more information, visit www.procyrion.com or call 713.579.9227.
ABOUT MILLAR
Since 1969, Millar, Inc. has led the development of catheter-based, solid-state pressure sensors and is known worldwide as the leader in sensors that advance medical understanding. Millar OEM serves the medical device and life sciences industries through our MEMS pressure sensors, ISO 13485 precision manufacturing and wireless power technology resulting in cost savings and rapid time to market for device integration.
Media Contact
Company Name: Procyrion, Inc.
Contact Person: Dana Summers
Email: dana@penmanpr.com
Phone: 334-663-4424
Address:3900 Essex Lane Suite 575
City: Houston
State: TX
Country: United States
Website: www.procyrion.com